Protagonist Therapeutics - 48 Year Dividend History | PTGX

Historical dividend payout and yield for Protagonist Therapeutics (PTGX) since 1971. The current TTM dividend payout for Protagonist Therapeutics (PTGX) as of April 18, 2019 is $0.00. The current dividend yield for Protagonist Therapeutics as of April 18, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.244B $0.031B
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $109.312B 12.32
Gilead Sciences (GILD) United States $80.293B 10.22
Bio-Techne Corp (TECH) United States $7.144B 48.13